References
- Peyrin-Biroulet L, Reinisch W, Colombel J-F, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut [Internet]. 2014 Jan [cited 2014 Nov 14];63(1):88–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23974954
- Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155. 2010/07/20 ed.
- Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):438–444.
- Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis [Internet]. 2011 Oct [cited 2014 Nov 14];5(5):477–483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21939925
- Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther [Internet]. 2005 Feb [cited 2015 Dec 16];312(2):537–545. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15388785
- Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol [Internet]. 2005 Aug [cited 2015 Dec 16];20(8):1149–1157. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16048561
- Kröplin T, Iven H. Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors. Eur J Clin Pharmacol [Internet]. 2000 Jul [cited 2015 Dec 16];56(4):343–345. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10954350
- Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut [Internet]. 2002 Apr [cited 2015 Dec 16];50(4):485–489. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1773162&tool=pmcentrez&rendertype=abstract
- Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther [Internet]. 1989 Aug [cited 2015 Dec 16];46(2):149–154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2758725
- Gilissen LPL, Wong DR, Engels LGJB, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis [Internet]. 2012 Jul [cited 2015 Aug 20];6(6):698–707. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/22398098
- Roblin X, Oussalah A, Chevaux J-B, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis [Internet]. 2011 Dec [cited 2015 Aug 20];17(12):2480–2487. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21351210
- Dassopoulos T, Sultan S, Falck–Ytter YT, et al. American gastroenterological association institute technical review on the use of thiopurines, methotrexate, and Anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology [Internet]. 2013 Dec [cited 2015 Oct 17];145(6):1464–78.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24267475
- Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60(7):930–936.
- Ramadas AV, Gunesh S, Thomas GAO, et al. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. BMJ Group;. 2010;59(9):1200–1206.
- Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology [Internet]. 2013 Oct [cited 2015 Aug 18];145(4):766–74.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23770132
- Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology [Internet]. 2013 Oct [cited 2015 Aug 18];145(4):758–65.e2; quiz e14–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23644079
- Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet [Internet]. 2015 Sep 2 [cited 2015 Sep 10]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26342731
- Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis [Internet]. 2009 Mar [cited 2015 Aug 18];15(3):375–382. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19009634
- D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc [Internet]. 1999 Nov [cited 2015 Aug 18];50(5):667–671. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10536324
- Laharie D, Reffet A, Belleannée G, et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther [Internet]. 2011 Mar [cited 2015 Aug 18];33(6):714–721. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21235604
- Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med [Internet]. 2010/04/16 ed. 2010;362(15):1383–1395. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0904492
- Colombel J-F. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther [Internet]. 2015 Apr [cited 2015 Aug 18];41(8):734–746. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25728587
- Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;2(7377):1273–1276.
- Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology [Internet]. 2000 Apr [cited 2015 Dec 16];118(4):705–713. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10734022
- Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis [Internet]. 2013 Jun [cited 2015 Dec 16];19(7):1404–1410. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23665964
- Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther [Internet]. 2008 Sep 1 [cited 2015 Dec 16];28(5):623–628. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18513380
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet [Internet]. 2009 Nov 7 [cited 2015 Apr 9];374(9701):1617–1625. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19837455
- Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011/06/29 ed. 2011;141(5):1621–1625.
- Lopez A, Mounier M, Bouvier A-M, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol [Internet]. 2014 Aug [cited 2015 Aug 18];12(8):1324–1329. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24582568
- Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis [Internet]. 2014 Jan [cited 2015 Apr 27];8(1):31–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721759
- Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigators. N Engl J Med [Internet]. 1995 Feb 2 [cited 2015 Aug 6];332(5):292–297. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7816064
- Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s study group investigators. N Engl J Med [Internet]. 2000 Jun 1 [cited 2015 Aug 6];342(22):1627–1632. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10833208
- Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis [Internet]. 2016 Jan [cited 2015 Dec 16];22(1):224–233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26457382
- Feagan BG, Jwd M, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology [Internet]. 2014 Mar [cited 2014 Oct 18];146(3):681–8.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24269926
- Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol [Internet]. 2010 Dec [cited 2015 Aug 18];53(6):1035–1040. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20801541
- Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis [Internet]. 2012 Feb [cited 2015 Aug 18];18(2):359–367. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21751301
- Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol (Hoboken, NJ) [Internet]. 2014 Apr [cited 2015 Aug 18];66(4):803–812. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24757133
- McSharry K, Dalzell AM, Leiper K, et al. Systematic review: the role of tacrolimus in the management of Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2011 Dec [cited 2015 Aug 20];34(11–12):1282–1294. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21999607
- Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology [Internet]. 2003 Aug [cited 2015 Aug 20];125(2):380–388. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12891539
- González-Lama Y, Abreu L, Vera MI, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis [Internet]. 2005 Jan [cited 2015 Aug 20];11(1):8–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15674108
- Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis [Internet]. 1999 Nov [cited 2015 Aug 20];5(4):239–245. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10579116
- Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn’s disease. Gut [Internet]. 2000 Sep [cited 2015 Aug 20];47(3):436–440. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1728043&tool=pmcentrez&rendertype=abstract
- Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment Pharmacol Ther [Internet]. 2007 Mar 1 [cited 2015 Aug 20];25(5):557–567. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17305756
- Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis [Internet]. 2007 Mar [cited 2015 Aug 20];13(3):245–253. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/17206671
- Tamaki H, Nakase H, Matsuura M, et al. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn’s disease. J Gastroenterol [Internet]. 2008 Jan [cited 2015 Aug 20];43(10):774–779. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18958546
- Mansfield JC, Parkes M, Hawthorne AB, et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2007 Aug 1 [cited 2015 Aug 20];26(3):421–430. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17635377
- Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther [Internet]. 2007 Feb 15 [cited 2015 Aug 20];25(4):419–427. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17269997
- Felipez LM, Gokhale R, Tierney MP, et al. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr [Internet]. 2012 Jan [cited 2015 Aug 20];54(1):28–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21681114
- Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012/02/14 ed. 2012;142(5):1102–11e2.
- Sandborn WJ, Lomax K, Pollack PF, et al. CJF. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn’s disease: data from extend. Gut. 2011;60:A136–A1.
- Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the paris definition of early Crohn’s disease for disease-modification trials. Am J Gastroenterol. 2012;107(12):1770–1776. 2012/12/06 ed.
- Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30(Suppl 3):67–72. 2013/01/18 ed
- Jauregui-Amezaga A, Rimola J, Ordás I, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut [Internet]. 2015 Sep [cited 2015 Oct 17];64(9):1397–1402. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25516418
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol [Internet]. 2015 Aug 25 [cited 2015 Sep 2];110(9):1324–1338. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26303131
- Colombel J-F, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol [Internet]. 2014 Mar [cited 2015 Apr 25];12(3):414–22.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23856361
- Hommes D, Colombel J-F, Emery P, et al. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis [Internet]. 2012 Mar [cited 2015 Mar 31];6 Suppl 2:S224–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22463929
- Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis [Internet]. 2012 [cited 2013 Jan 21];30(Suppl 3):67–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23295694
- Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. This Phase 2 study demonstrated the potential benefits in reducing inflammatory activity of Tofacitinib in CD, remission rates are not significantly better. Clin Gastroenterol Hepatol [Internet]. 2014 Sep [cited 2015 May 4];12(9):1485–93.e2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24480677
- Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med [Internet]. 2012 Aug 16 [cited 2015 May 4];367(7):616–624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22894574
- Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest [Internet]. 2001 Aug [cited 2015 Aug 14];108(4):601–609. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=209401&tool=pmcentrez&rendertype=abstract
- Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem [Internet]. 2004 Feb 6 [cited 2015 Aug 20];279(6):3925–3932. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14600158
- Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology [Internet]. 2006 Dec [cited 2015 Aug 20];131(6):1786–1798. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17087939
- Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2012 Nov [cited 2015 Aug 20];36(9):850–857. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22971085
- Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease. N Engl J Med [Internet]. 2015 Mar 19 [cited 2015 Mar 19];372(12):1104–1113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25785968
- D’Haens G, Sandborn WJ, Colombel JF, et al. A phase II study of laquinimod in Crohn’s disease. Gut [Internet]. 2015 Aug [cited 2015 Dec 16];64(8):1227–1235. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4515993&tool=pmcentrez&rendertype=abstract
- Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut [Internet]. 2012 Jun [cited 2015 Apr 27];61(6):918–932. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22115827
- Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008/10/14 ed. 2008;135(5):1493–1499.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002/06/06 ed. 2002;359(9317):1541–1549.
- Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol [Internet]. 2013 Jul [cited 2015 May 4];29(4):397–404. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23695427
- Peyrin-Biroulet L. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. Am J Gastroenterol [Internet]. 2013 May [cited 2014 Nov 14];108(5):859–860. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23644972